MT2005-18: TRANSPLANTATION OF UMBILICAL CORD BLOOD FOR MYELOID LEUKEMIA PATIENTS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究进一步发展了先前的研究(MT2003-01和MT2004-25)，这些研究旨在确定特定的准备方案(环磷酰胺和氟达拉滨)是否可以创造一个输注NK细胞的环境，使其能够生长并有效地治疗复发的AML患者。这项研究将使用完全的造髓准备方案(类似于我们的造髓脐带血方案MT2005-10)来测试NK细胞。我们正在专门研究标准的脐带血造髓准备方案能否成功地与脐血NK细胞和NK细胞前体细胞输注相结合。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study furthers the research of previous studies (MT2003-01 and MT2004-25) which were to determine whether a specific preparatory regimen (clyclophosphamide and fludarabine) could create an environment in which infused NK cells can grow and effectively treat patients with relapsed AML. This study will test the NK cells with a fully myeloblative preparative regimen (similar to our myeloblative cord blood protocol MT2005-10). We are specifically studying whether standard UCB myeloblative preparatory regimen can be successfully combined with an infusion of cord blood NK cells and NK cell precursor cells.